Jason Buxbaum, MHSA, project manager, V-BID Health; and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council, discuss low-value services, their financial impact, what states are doing to address them, and challenges with addressing them.
As conversations surrounding rising healthcare costs persist, the idea of addressing low-value services has caught the attention of health professionals nationwide. Value-Based Insurance Design (V-BID) Health’s Task Force on Low-Value Care has identified a top 5 list of low-value clinical services that can be targeted.
We spoke with Jason Buxbaum, MHSA, project manager, V-BID Health, about which 5 low-value services topped the list, the financial impact they have, and how states are attempting to address them.
Once low-value services are identified, healthcare professionals face another challenge: turning conversation into something actionable. We discussed the challenges with addressing these low-value services with Buxbaum and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access
July 11th 2025During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More